Nooma Bio Announces New Leadership Team to Advance Development of Dual-Nanopore Technology for Ultra High-Resolution Genome and Epigenome Mapping; DNA Sequencing Veteran Kevin Corcoran Joins As CEO

In a March 7, 2022 release, Nooma Bio, Inc., an innovator in the use of dual-nanopore technology to detect genome-wide structural and epigenetic variation, announced a new leadership team including DNA sequencing veteran Kevin Corcoran as Chief Executive Officer. Mr. Corcoran has more than 30 years of experience developing and commercializing advanced genomic technologies. Prior to joining Nooma, he served as Vice President and General Manager at Agilent Technologies and as Senior Vice President of Marketing at Pacific Biosciences. Before that, he was President and CEO of Lynx Therapeutics, where he was responsible for the development and commercialization of the company’s massively parallel short-read sequencing technology. He was also previously Vice President and General Manager of Applied Biosystems’ DNA Genetic Analysis business. He holds a BS in computer science from California State University.

Login Or Register To Read Full Story